Lexaria Bioscience Corp (LEXXW) stock forecast · rev $705.9K
Lexaria Bioscience Corp (LEXXW) common stock listed on US.
This LEXXW forecast page states what the cached financials imply — not a price target and not a guarantee. Lexaria Bioscience Corp outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported LEXXW revenue for 2025-08-31 was $705.9K. Net income was -$11.9M. Revenue was up 52.0% from 2024-08-31 to 2025-08-31. LEXXW currently screens at market cap $33.8M.
The near-term path: Revenue was up 52.0% from 2024-08-31 to 2025-08-31. A forecast that ignores that change is just a story.
LEXXW currently screens at market cap $33.8M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next LEXXW 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the LEXXW stock page.
Not investment advice.